Hirsch N, Nölle B, Zavazava N, Westphal E, Duncker G, Rochels R, Müller-Ruchholtz W
Klinik für Ophthalmologie, Universität Kiel.
Ophthalmologe. 1993 Apr;90(2):174-7.
Improved microsurgical techniques and better immunosuppressive treatment have led to an increase in the number of corneal transplantations. However, graft rejection due to a disparity between donor and recipient major histocompatibility antigens remains the major complication. The risk of graft rejection is further increased in patients with vascularized graft beds and in presensitized persons. Well-designed experimental studies and clinical experience have clearly shown the importance of class-I-antigens. However, class-II antigens have not yet been studied to the same extent.
Multiorgan donors and corneal graft recipients were HLA typed using the lymphocytotoxicity test previously described by Terasaki. The recipients were typed retrospectively. Cadaver corneal graft donors were typed using a novel HLA typing technique on retinal pigment epithelial cells, as previously described by us. Postoperatively, all recipients were routinely examined for rejection over a period of 2 years.
Graft rejection was observed in 25% of the 133 high-risk patients. Of the 13 class-I-typed patients who showed a rejection 9 persons had two or more major histocompatibility mismatches. Of the 12 patients without rejection problems only 5 had two or more HLA class-I-mismatches. Of the patients with one or two matches at the HLA-DR locus there were only 4 out of 9 patients with at least one graft rejection; 5 out of 6 patients showed no signs of rejection.
Mismatches at either class-I- or class-II- gene loci lead to a higher frequency in corneal graft rejection. Apart from the major histocompatibility mismatches, other factors also influence graft rejection, such as the distance between the corneal transplant and corneal vessels, presensitization, and the indication for corneal grafting. If we are to define the factors influencing graft rejection better and further increase our knowledge on the role the major histocompatibility antigens play in corneal graft rejection in a larger patient group, then cooperation with other transplantation centers will be required.
改进的显微外科技术和更好的免疫抑制治疗导致角膜移植数量增加。然而,由于供体和受体主要组织相容性抗原不匹配导致的移植物排斥仍然是主要并发症。血管化移植床患者和预致敏者的移植物排斥风险进一步增加。精心设计的实验研究和临床经验清楚地表明了I类抗原的重要性。然而,II类抗原尚未得到同样程度的研究。
使用Terasaki先前描述的淋巴细胞毒性试验对多器官供体和角膜移植受者进行HLA分型。对受者进行回顾性分型。如我们先前所述,使用一种新的HLA分型技术对尸体角膜移植供体的视网膜色素上皮细胞进行分型。术后,对所有受者进行为期2年的常规排斥反应检查。
133例高危患者中有25%发生了移植物排斥。在13例I类分型显示排斥反应的患者中,9人有两个或更多主要组织相容性错配。在12例无排斥问题的患者中,只有5人有两个或更多HLA I类错配。在HLA-DR位点有一个或两个匹配的患者中,9例至少有一次移植物排斥的患者中只有4例;6例患者中有5例没有排斥迹象。
I类或II类基因位点的错配导致角膜移植排斥的频率更高。除了主要组织相容性错配外,其他因素也影响移植物排斥,如角膜移植与角膜血管之间的距离、预致敏以及角膜移植的指征。如果我们要更好地定义影响移植物排斥的因素,并进一步增加我们对主要组织相容性抗原在更大患者群体的角膜移植排斥中所起作用的认识,那么就需要与其他移植中心合作。